FSGCY yields 4.63% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 10
Combined, FSGCY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FSGCY + JNJ for your $10,000?
First Gen Corporation, through its subsidiaries, engages in the power generation business in Philippines. It operates through FGPC, FGP, FNPC, Prime Meridian, EDC and Subsidiaries, and FG Hydro segments. The FGPC segment operates Santa Rita, a 1,000 MW combined cycle, natural gas-fired power plant. The FGP segment operates San Lorenzo, a 500 MW combined cycle, natural gas-fired power plant. The FNPC segment owns and operates San Gabriel plant, a 420 MW natural gas-fired power plant. The Prime Meridian segment owns and operates Avion plant, a 97 MW open-cycle natural gas-fired power plant. The EDC and Subsidiaries segment holds service contracts with the Department of Energy to explore, develop, and utilize the resources in the relevant 10 geothermal contract areas. This segment owns and operates 588.4 MW Unified Leyte geothermal power plants; 172.5 MW Palinpinon geothermal power plants; 140.0 MW Bac-Man geothermal power plants; 123.0 MW Tongonan geothermal power plant; 106.0 MW Mindanao geothermal power plants; 49.4 MW Nasulo geothermal power plant; 150 MW Burgos Wind Energy project; 6.82 MW Burgos Solar Energy project; and 5.17 MW Solar Rooftop projects. The FG Hydro segment operates Pantabangan-Masiway, a 132 MW Hydroelectric Plant. It sells its electricity to Manila Electric Company, National Power Corporation, electric cooperatives, privately-owned distribution utilities, large industrial clients, and National Grid Corporation of the Philippines. As of December 31, 2021, the company had an installed capacity of 3,495 megawatts (MW). First Gen Corporation was incorporated in 1998 and is based in Pasig, the Philippines. First Gen Corporation is a subsidiary of First Philippine Holdings Corporation.
Full FSGCY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.